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ABSTRACT
Objectives: To compare availability, cost, affordability and sources of anti-diabetic 
drugs between private and public health facilities in Dar es Salaam, Tanzania. 
Design: Cross sectional descriptive study.
Setting:  Diabetic clinics in private and public health facilities in Dar es Salaam, 
Tanzania. 
Subjects:  Eighty patients randomly selected and 45 health facility personnel staff 
working in the diabetic clinics. Semi-structured questionnaires and a checklist were 
used to collect the information.
Results: Oral hypoglycaemic agents were available in all seven private and three public 
facilities that were studied. Private facilities stocked more types of oral hypoglycaemic 
agents than public facilities, which stocked only chlorpropamide and tolbutamide, 
based on the National Essential Drugs List. The cost of chlorpropamide was five times 
higher in private facilities compared to public facilities. Insulin was also available in 
all the facilities. The price of animal insulin in private health facilities was ten times 
that in public health facilities. Human insulin, which is generally more expensive than 
animal insulin, was only available in private facilities.  Although prices were much 
lower in public facilities, affordability emerged as a common issue in both private 
and public facilities.
Conclusions: Urban private health facilities offer a wider choice for the needs of 
diabetic patients but this advantage is compromised by higher prices as compared to 
public facilities as well as inconsistent supply across facilities. Public health facilities 
offer only a limited selection of essential oral hypoglycaemics and insulin but at a 
lower price and across all facilities. Twenty six per cent and 10% of patients in public 
and private facilities respectively are unable to afford anti-diabetic drugs. The need 
for intervention to increase affordability of anti-diabetic drugs is evident. Financing 
and cost of drugs needs to be addressed, either by means of health insurance or 
other mechanisms, in this era of increasing prevalence of diabetes mellitus among 
developing countries. 
INTRODUCTION
In 2003, the prevalence of diabetes for all age 
groups worldwide was estimated at 5.1%. The 
number of deaths attributed to diabetes worldwide 
was estimated to be 1.1 million in 2005 (1). 
Globally in the year 2003 the number of people 
with diabetes was estimated to be 194 million. 
The World Health Organisation (WHO) and the 
International Diabetes Federation (IDF) project 
that the number of diabetic patients may double 
by the year 2030, and suggest the need to prepare 
national health services for the projected increase. 
Almost 80% of deaths related to diabetes occur in 
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low and middle income countries (1). Although 
diabetes is sometimes considered a condition of 
developed nations, the loss of life from premature 
death among persons with diabetes is greatest in 
developing countries.
 The prevalence of type 1 and type 2 diabetes 
in African countries (urban and rural) varies 
considerably, but it was estimated to be in the 
dimension of 0.01-1.0% in Tanzania in 1996 (2). The 
percentages of all deaths associated with diabetes in 
Dar es Salaam were estimated to be 2.6% for males 
and 1.7% for females (2).  The estimated number of 
diabetics in Tanzania in 2000 was 201,000 and based 
on about 6.7% annual growth rate, it is projected that 
the number will rise to 605,000 in 2030. 
 A recent survey revealed that only 3% of people 
with diabetes in developing countries are treated 
with anti-diabetic drugs, as compared to 13% in the 
developed world. The reasons are complex, ranging 
from culturally based misconceptions to chronic 
shortages of drugs which may be due to lack of finance 
in the health sector, poor procurement or ineffective 
distribution and inadequate storage (3). Access to 
drugs can be defined as availability, geographical 
accessibility, affordability (ability to pay) and cultural 
acceptability. 
 Drugs are the mainstay of diabetes treatment, 
therefore they need to be available, easily accessible, 
affordable and culturally suitable to diabetic patients 
who need treatment throughout their lives (4).  The 
cost of diabetes affect all patients everywhere and 
not only include financial difficulties. Intangible costs 
such as pain, anxiety, inconvenience and generally 
lower quality of life also have great impact on the lives 
of patients and their families and are the most difficult 
to quantify (5). Insulin is a costly medication and is 
unavailable or unaffordable in many poor countries, 
despite being listed by WHO as an essential drug 
(1). The price of insulin without syringe, need and 
necessary equipment for monitoring blood glucose 
levels varies widely from country to country, ranging 
from less than US$ 3 to US$ 45 a vial. However, in 
many African countries the cost of a vial of insulin 
may be the equivalent of a month’s salary (1). In 
Tanzania, with cost-sharing schemes in the public 
health sector, the cost of one vial of animal insulin is 
about US$ 1 (6).  Diabetes and its complications impose 
significant economic consequences on individuals, 
families, health systems and countries (1).
 Government health facilities in Tanzania buy 
drugs based on the National Essential Drugs List 
including anti-diabetic drugs from the Medical 
Stores Department. Patients currently get drugs from 
government health facilities under a cost-sharing 
scheme whereby they are required to pay 50% of the 
actual price of the drugs (6).  Private health facilities do 
not purchase their medicines from MSD; instead they 
purchase from private wholesale, retail pharmacies 
and other sources of drug supply. This removes 
monopoly and allows more drugs to be available, but 
there are significant differences in terms of availability 
and cost of drugs between the two sectors.  In the 
private sectors patients are required to pay the full 
cost of the drugs out of pocket. All drugs on the local 
market have to be registered by the Tanzanian Food 
and Drug Authority.
MATERIALS AND METHODS
Study population: The survey was conducted in the 
three district hospital facilities in Dar es Salaam city 
namely Amana (Ilala), Temeke and Mwananyamala 
(Kinondoni) in the public sector, and in seven 
randomly selected private facilities, two hospitals 
and five health centres in 2003.  The study involved 
80 patients attending diabetes clinics, both in public 
and private sectors and 45 staff in-charge of the 
clinics and pharmacists/pharmaceutical technicians 
responsible for handling anti-diabetic drugs. 
Data collection: Face to face interviews using semi-
structured open and closed ended questionnaires were 
used to collect information from patients, medical 
officers in charge of diabetes clinics and pharmacists/
pharmaceutical assistants responsible for handling and 
dispensing hypoglycaemic agents both in public and 
private health facilities. Drug records were viewed, 
checked on reliability and compared to the information 
given by respondents. All subjects were informed about 
the contents of the interview and aims of the study 
before participation. They were also asked for  consent 
to participate in the study to guarantee voluntary 
participation, assured anonymity, confidentiality and 
were given opportunity to comment on what they 
had been asked during the interview. Study questions 
included availability, cost, affordability and sources of 
anti-diabetic drugs. 
RESULTS
The mean number of 23 diabetic patients who 
attended private facilities was lower than 106 who 
attended in public facilities during the study period. 
Nineteen patients attending private facilities and 
61 patients attending public health facilities were 
interviewed. Eighty three of patients attending private 
facilities were type 2 diabetic patients and 17% were 
type 1 patients. More  patients from both private and 
public health facilities use oral hypoglycaemic agents 
than insulin injections. In private facilities about 53% 
use oral hypoglycaemics compared to 59% in public 
hospitals. In private facilities 42% of patients use 
insulin injections, while 38 % of patients in public 
facilities use insulin (Table 1).
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The survey showed that both insulin and oral 
hypoglycaemic agents were available in all private and 
public facilities.  Seven types of oral hypoglycaemic 
agents were found in private facilities as compared 
to two types in public facilities; chlorpropamide 
and tolbutamide.  Both private and public facilities 
provided insulin, but human insulin was only 
available in three out of seven (43%) private health 
facilities while none of the public heath facilities had 
human type of insulin (Table 3).  
 The main sources of anti-diabetic drugs in 
private facilities were wholesale pharmacies (57%) 
and retail pharmacies (43%), while public health 
facilities received their drugs from the medical stores 
department. 
 The mean price of animal Actrapid insulin in 
private facilities was US$ 5.45 per vial while in public 
facilities the mean cost for the same drug was US$ 0.55. 
In the private facilities animal Lente insulin was sold 
at a mean price of US$ 5.60 while in public facilities 
it was sold at a price of US$ 0.55. Chlorpropamide 
at 250 mg tablet was sold at US$ 0.09 per tablet in 
private facilities while in public facilities the mean 
price was US$ 0.02 (Table 4). 
Table 1
Types of anti-diabetic drugs used by patients in three public and seven private facilities
  Number of patients
Type of drug Private facilities (%) Public facilities (%)
Insulin 8 42.1 23 38
Oral hypoglycaemics 10 52.6 36 59
Both insulin and oral hypoglycaemics 1 5.3 2 3
Total 19 100 61 100
Table 2
Patients’ responses pertaining to availability of anti-diabetic drugs in private and public facilities
Availability  Number of patients
 Private facilities (%) Public facilities (%)
Always available 17 89.5 32 52.4
Seldom available 2 10.5 25 41.0
Not available at all 0 0 4 6.6
Total 19 100 61 100
Table 3
Anti-diabetic drugs available in private and public facilities
Type of drug  Health facility
 Private (n=7) (%) Public (n =3) (%)
Insulin    
   Animal 7 100 3 100
   Human 3 42.9 - 0
Oral drugs    
   Acarbose 3 42.9 - 0
   Chlorpropamide   250mg 6 85.7 3 100
   Glibenclamide 5mg 5 71.4 - 0
   Gliclazide 80mg 3 42.9 - 0
   Glipizide 5mg 5 71.4 - 0
   Metformin 500mg 7 100 - 0
   Tolbutamide 500mg 1 14.3 3 100
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Table 4
Costs of anti-diabetic drugs in private and public health facilities (US$ per tablet or vial)
Type of Drug Cost of drugs in  Cost of drugs in 
 private health facilities  public health facilities
 Mean   Mean 
 price Min Max price Min Max
Insulin      
  Pork Actrapid  30/70 40 IU/units 5.45 3 8.50 0.55 0.50 0.65
  Pork Lente 40 IU/units 5.60 3 8.50 0.55 0.50 0.65
  Human mixtard  30/70 100 IU/units 24.80 24.80 24.80 - - -
  Humulin 30/70 100 IU/units 30.00 30.00 30.00 - - -
  Humulin regular 100 IU/units 36.00 36.00 36.00 - - -
Oral drugs      
  Acarbose 50mg 0.35 0.35 0.35 - - -
  Chlorpropamide 250mg 0.094 0.05 0.10 0.019 0.017 0.02
  Glibenclamide 5mg 0.0275 0.02 0.05 - - -
  Gliclazide 80mg 0.223 0.03 0.145 - - -
  Glipizide 5mg 0.082 0.05 0.1 - - -
  Metformin 500mg 0.087 0.015 0.10 - - -
  Tolbutamide 500mg - - - 0.019 0.017 0.02
 Table 5
Affordability of anti-diabetic drugs in three private and seven public health facilities
Affordability           Number of patients
 Private facilities (%) Public facilities (%)
Able to pay 17 89.5 45 73.8
Unable to pay 2 10.5 16 26.2
Total 19 100 61 100
 
Responses by pharmacists/pharmaceutical 
technicians revealed that there were no complaints 
from patients in private facilities about availability 
of anti-diabetic drugs. In private facilities the cost 
of drugs was the most common complaint, and 
affordability came up as an issue in four facilities.  On 
the other hand, in all three public facilities, the most 
common complaint was non-availability of medicines. 
No complaints about the cost and affordability of 
drugs were observed in public facilities. 
 From a patient point of view, 90% of patients 
indicated that anti-diabetic drugs were always 
available at private facilities, while 11% said that 
the drugs were seldom available. In public facilities 
52% of patients said that the drugs are always 
available, 41% said they were seldom available and 
7% said the drugs they are using are not available 
at all (Table 2).
 Close to 90% of patients from both private and 
over two thirds of patients from the public facilities 
said they were able to pay for anti-diabetic drugs. 
About 26% of patients in the public facilities had 
problems in paying for their medications compared 
to 11% in the private facilities (Table 5).
DISCUSSION
This cross sectional descriptive study aimed at 
determining availability, cost, affordability and 
sources of anti-diabetic drugs in private and public 
health facilities in Dar es Salaam. 
 Generally both private and public health facilities 
had drugs available for managing diabetic patients 
as described in the National Essential Drug List. 
However, there were differences in the variety of oral 
hypoglycaemic agents, with private facilities having 
a wider selection of drugs.  Similarly human insulin 
was only available in private facilities. 
 Availability of human insulin and of more 
types of oral hypoglycaemic drugs in the private 
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facilities is explained by free market mechanisms 
in the private sector and the implementation of the 
National Essential Drug List in the public sector 
based on national resources. Public health facilities 
receive their drugs from MSD that distributes only 
essential drugs and the selection of which is based on 
an efficacy and cost-benefit analysis. Private facilities 
depend on  private wholesale and retail pharmacies 
for their supply. The selection is determined by 
national regulation and purchasing power of the 
patients. 
 The availability of only two types of anti-diabetic 
drugs in the public facilities may restrict medical 
choice for treating diabetics based on specific patient 
needs.  On the other hand, the National Essential Drug 
List is based on best evidence and adapted to available 
resources of a country. Availability of a limited number 
of only essential drugs in the public sector allows for 
continuity and consistency. Availability of more types 
of drugs in the private sector limits access for poor 
patients owing to the fact that most of the drugs that 
are not on the essential drugs list are expensive. The 
selection of drugs available on the market should be 
based on treatment guidelines.
  The mean cost of anti-diabetic drugs was 
significantly higher in private compared to public 
health facilities. The price of animal insulin in 
private health facilities was ten times that in public 
health facilities, while that of chlorpropamide was 
five times higher in private facilities than in public 
facilities. It was also found that in private facilities, 
the price of human insulin is higher than that of 
animal insulin. The mean price of human regular 
insulin was US$ 36.00, which, is  seven times the 
mean price of animal insulin in private facilities and 
sixty five times the mean price of animal insulin in 
public facilities. Other researchers have reported 
similar costs of insulin (1, 6). 
 This cost difference has an important impact 
on access to anti-diabetic drugs. The costs observed 
above may explain why more patients attend public 
health facilities compared to private facilities, and 
why most of the patients used animal insulin rather 
than human insulin. 
 The differences in affordability (ability to pay) 
may be due to differences in social and economic 
status of patients attending public and private health 
facilities. It is well documented that affordability of 
anti-diabetic drugs is an important determinant in 
the whole process of management of diabetes (1, 8, 
9). Promoting the use of animal insulin instead of 
human insulin in both private and public facilities 
can reduce the difference in affordability.
 The fact that 36% of all patients declared they 
had problems paying for medicine reflects what other 
researchers state that, although poverty is less acute in 
the urban area, it is still a serious problem (10, 11).
In conclusion, the study results showed that there is 
an important difference of medicine availability for 
management of diabetes mellitus between private 
and public health facilities in Dar es Salaam. Costs 
of anti-diabetic drugs differ significantly between 
public and private facilities. Inability to pay for anti-
diabetic drugs remains a reality for 26% and 10% of 
patients in public and private facilities respectively. 
If access is to be assured for all now and in the years 
to come, financing and cost of anti-diabetic drugs 
will have to be reassessed. Health insurance, and 
possibly, more rigorous price control mechanisms 
may be needed to enable all diabetic patients to get 
the medicine they need. 
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